FIELD: chemistry.
SUBSTANCE: invention relates to heterocyclic compounds with general formula (I) 
or its pharmaceutically acceptable salts; and including its any stereoisomer forms;X and Y are independently N or CR1; Z represents S, O, NR1 or CR1 2;every R1-R6 represent independently H or not influencing substitute, which is alkyl (C1-10), allkenyl (C2-10), alkynil (C2-10), aryl ("C'5-12), arylalkyl, arylalkenyl or arylalkynil, each of which can not obligatorily contain one or more heteroatoms selected from O, S and N and each of which can be substituted further one; or not obligatorily substituted forms of acyl, arylacyl, alkyl,alkenyl alkynyl or arylsulphonyl or their forms which contain heteroatoms in alkyl,alkynyl or aryl fragments or representing OR, SR, NR2, COOR, CONR2, where R is N or alkyl alkenyl, alkynyl, or aryl not obligatorily substituted, as defined above, when C is a substituted atom not influencing substitute can be a halohen, OOCR, NROCR, where R is H or its substitute shown above, or can equal 0; nl is equal to 0-4; n2 is equal to 0-1, where * means that CR5=CR5 can be substituted by C=C; n3 is equal to 0-4;where nl+n2+n3 exceeds or equals 2; b is equal to 0-2; where the following combinations of R-groups can be associated with cycle formation, which can saturated or unsaturated R2-R2, one R2+R3, R3+ one R4, R4+R4, one R5 + the other R5, one R5 + one R6 and R6+R6; where cycle can not be aromatic, when the cycle formation components are represented by two R5; and where, when n2 is unity 1, neither of n1 nor n3 can be equal to 0, the invention also relates to pharmaceutical composition, based on these compounds, possessing a modulating ability relative to CXCR4- and/or CCRS-receptor; to modulation method CXCR4- and/or CCRS-receptor; to method of treatment of a statec described by unusual activity CXCR4- and/or CCR5-receptor and application of the described compounds for production of pharmaceutical.
EFFECT: new compounds feature useful biological properties.
36 cl, 171 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HETEROCYCLIC COMPOUNDS MODULATING ACTIVITY OF CHEMOKINE RECEPTOR, THEIR USING AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | 2001 |
|
RU2297413C2 |
| HETEROCYCLIC COMPOUNDS, THEIR USING AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF STATES MEDIATED BY CXCR4 AND CCR5 | 2001 |
|
RU2277092C2 |
| HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF AND THEIR USING | 2001 |
|
RU2289581C2 |
| METHODS FOR PRODUCTION OF RACEMIC AMINOSUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE OR RACEMIC AMINOSUBSTITUTED 5,6,7,8-TETRAHYDROISOQUINOLINE, METHODS FOR SEPARATION AND RACEMIZATION THEREOF, METHODS FOR PRODUCTION OF KETOSUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE OR KETOSUBSTITUTED 5,6,7,8-TETRAHYDROISOQUINOLINE, METHOD FOR PRODUCTION OF ENANTIOMER PF CONDENSED BYCYCLIC RING SUBSTITUTED WITH PRIMARY AMINE, 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES | 2002 |
|
RU2308451C2 |
| SUBSTITUTED PYRIMIDINETHIOALKYL OR ALKYLESTER COMPOUNDS AND METHOD OF INHIBITION OF VIRAL REVERSE TRANSCRIPTASE ACTIVITY | 1996 |
|
RU2167155C2 |
| 2,6-SUBSTUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | 2005 |
|
RU2417990C2 |
| 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5-HT3 MODULATORS | 2007 |
|
RU2448105C2 |
| BENZOFURAZAN ANTIMYLOID COMPOUNDS AND METHODS | 2013 |
|
RU2641293C2 |
| PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | 2006 |
|
RU2420519C2 |
| DERIVATIVES OF TETRAHYDROQUINOLINE SHOWING PROTECTIVE ACTION FROM HIV-INFECTION | 2005 |
|
RU2350604C2 |
